Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Asset Utilization Ratio (2016 - 2026)

Neurocrine Biosciences filings provide 15 years of Asset Utilization Ratio readings, the most recent being 0.64 for Q4 2025.

  • On a quarterly basis, Asset Utilization Ratio fell 0.98% to 0.64 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.64, a 0.98% decrease, with the full-year FY2025 number at 0.69, up 1.38% from a year prior.
  • Asset Utilization Ratio hit 0.64 in Q4 2025 for Neurocrine Biosciences, down from 0.66 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 0.67 in Q2 2023 to a low of 0.45 in Q2 2022.
  • Median Asset Utilization Ratio over the past 5 years was 0.6 (2024), compared with a mean of 0.59.
  • Biggest five-year swings in Asset Utilization Ratio: decreased 22.36% in 2021 and later surged 48.76% in 2023.
  • Neurocrine Biosciences' Asset Utilization Ratio stood at 0.55 in 2021, then decreased by 9.6% to 0.5 in 2022, then grew by 23.48% to 0.62 in 2023, then grew by 4.95% to 0.65 in 2024, then decreased by 0.98% to 0.64 in 2025.
  • The last three reported values for Asset Utilization Ratio were 0.64 (Q4 2025), 0.66 (Q3 2025), and 0.66 (Q2 2025) per Business Quant data.